Illes A, Varoczy L, Papp G, Wilson P C, Alex P, Jonsson R, Kovacs T, Konttinen Y T, Zeher M, Nakken B, Szodoray P
Division of Immune-Hematology, 3rd Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Scand J Immunol. 2009 May;69(5):387-400. doi: 10.1111/j.1365-3083.2009.02237.x. Epub 2009 Feb 6.
The development of B-cell lymphomas is an intricate interplay among various pathogenic factors, leading to a multi-step process, encompassing various stages of B-cell maturation. Besides genetic abnormalities, a variety of environmental and microbial factors, as well as disproportional immune-regulatory processes lead to the malignant transformation. Yet, little is known about the exact chain of events, which lead from the physiological polyclonal B-cell activation as a response to exogenous antigens through oligoclonality to a monoclonal, uncontrolled, malignant B-cell proliferation. The aim of the present review was to summarize the potential harmful steps in the development of B-cell lymphomas, according to conventional and novel theories, and to depict therapeutic regimens presently in use as well as to envision future drug developments, beneficial in the battle against this lymphoid malignancy.
B细胞淋巴瘤的发展是多种致病因素之间复杂的相互作用，导致一个多步骤过程，涵盖B细胞成熟的各个阶段。除了基因异常外，多种环境和微生物因素以及免疫调节过程失衡也会导致恶性转化。然而，对于从对外源抗原的生理性多克隆B细胞激活通过寡克隆性到单克隆、不受控制的恶性B细胞增殖这一确切事件链，人们知之甚少。本综述的目的是根据传统和新理论总结B细胞淋巴瘤发展过程中潜在的有害步骤，描述目前使用的治疗方案，并展望未来在对抗这种淋巴恶性肿瘤方面有益的药物开发。
